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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effects of exercise interventions for improving maternal and fetal outcomes in women with pre-existing diabetes.
B A C K G R O U N D
The original review, Exercise for diabetic pregnant women (
Ceysens 2006), has been split into two new review titles, to reflect
the role of exercise for pregnant women with gestational diabetes
and for pregnant women with pre-existing diabetes.
• Exercise for pregnant women with gestational diabetes for
improving maternal and fetal outcomes (Ceysens 2016)
• Exercise for pregnant women with pre-existing diabetes for
improving maternal and fetal outcomes (this review)
There will be similarities in the background, methods and out-
comes between these two systematic reviews. Portions of themeth-
ods section of this protocol are based on a standard template used
by the Cochrane Pregnancy and Childbirth Review Group.
Description of the condition
Diabetes and pregnancy
It is estimated that 2% to 5% of pregnant women have pre-ex-
isting or gestational diabetes (CEMACH 2007). Up to 0.4% of
women in the UK and 0.9% of pregnant women in the USA and
have pre-existing diabetes (type 1 or type 2; CEMACH 2007;
Correa 2015). The prevalence of type 1 and type 2 diabetes is in-
creasing. The number of pregnant women with pre-existing type
2 diabetes more than quadrupled in the USA between 1994 and
2004, overtaking the rates of pre-existing type 1 diabetes (0.42%
versus 0.33%; Albrecht 2010). This increase in type 2 diabetes in
pregnant women has been partly attributed to increasing obesity
and older mothers (ACOG 2005; Zhu 2016). Type 2 diabetes has
particularly increased in certain minority ethnic groups (including
people of African, black Caribbean, South Asian, Middle East-
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ern, and Chinese family origin; CEMACH 2007). An association
between type 2 diabetes and socioeconomic status has also been
noted (Correa 2015; Murphy 2009).
Type 1 diabetes tends to begin in childhood, while type 2 dia-
betes mellitus usually occurs later in adulthood. In type 1 dia-
betes, sudden onset of insulin deficiency is believed to be caused by
an autoimmune attack of the insulin-producing pancreatic beta-
cells (cells that store and release insulin; Galerneau 2004; Griffith
2004). In type 2 diabetes, tissues become resistant to the action
of insulin and insulin secretion is disrupted, leading to increasing
levels of glucose in the blood (Dunne 2005).
Gestational diabetes is characterised by glucose intolerance that
begins or is first detected during pregnancy. The incidence of ges-
tational diabetes is also increasing as a result of higher rates of
obesity in the general population, and more pregnancies in older
women. After a pregnancy with gestational diabetes, women have
an increased risk of progression to ‘pre-existing’ diabetes (i.e. type
2 diabetes) in the next pregnancy (Khambalia 2013).
Adverse outcomes for women and infants associated
with pre-existing diabetes
Pregnancies with pre-existing diabetes are high risk, with increased
risk of poorer fetal, neonatal, and maternal outcomes (Owens
2015). Women with type 1 diabetes have an elevated risk of preg-
nancy loss, perinatal mortality, fetal macrosomia (a fetus that is
large-for-gestational age), and congenital malformations (NICE
2015; Platt 2002). This is also the case for women with pre-ex-
isting type 2 diabetes (CEMACH 2007; Inkster 2006), although
neonatal outcomes may be poorer when the mother has type 1
diabetes (Owens 2015). However, a systematic review found peri-
natal mortality to be higher for women with type 2 compared with
type 1 diabetes (odds ratio 1.50, 95% confidence interval 1.15 to
1.96; Balsells 2009).
Organogenesis (development of organs) in early pregnancy can be
affected by metabolic disruptions when there are high concentra-
tions of maternal blood glucose. Cardiovascular malformations are
the most common birth defects in infants born to diabetic moth-
ers (Inkster 2006). Apart from macrosomia (high birthweight, of-
ten defined as more than 4000 g), other adverse outcomes for in-
fants may include large-for-gestational age, shoulder dystocia (dif-
ficulty in delivering shoulders of baby), neonatal hypoglycaemia
(blood sugar that is lower than normal), preterm birth, hyper-
bilirubinaemia (excess bilirubin), hypocalcaemia (lower than nor-
mal calcium), and neonatal intensive care admission (Jensen 2004;
Macintosh 2006; Ray 2001; Walkinshaw 2005; Weintrob 1996).
Long-term follow-up of the infants of diabetic mothers suggests
that they may also have an increased risk of obesity and type 2
diabetes when older (Dabelea 2000).
In pregnant women with type 1 (insulin-dependent) diabetes, in-
sulin is used to control fluctuations in blood glucose concentra-
tions throughout the day (Galerneau 2004). In type 2 diabetes,
lifestyle changes (including diet and exercise) are the first line of
treatment, with the option of using oral hypoglycaemic agents or
insulin to lower blood glucose if necessary. Therefore, manage-
ment of diabetes in pregnancy aims for control of glucose concen-
trations using careful combinations of diet, exercise, and insulin
or other anti-diabetogenic drugs, if required (ACOG 2005; NICE
2015).
Description of the intervention
The AmericanCollege of SportsMedicine defines physical activity
as any bodily movement that is produced as a result of the con-
traction of skeletal muscle, and defines exercise as physical activity
comprising planned, structured, and repetitive body movements,
which are undertaken to improve one or more components of
physical fitness (ACSM 2014).
Physical activity in non-diabetic pregnant women has been shown
to be beneficial. It was not shown to be harmful to the fetus and
can potentially lead to long-term health benefits for the mother.
Benefits observed include cardio-respiratory fitness, prevention
of stress urinary incontinence, prevention of lumbar pain, de-
creased depression, and control of weight gain during pregnancy
(Nascimento 2012).
In women with type 2 diabetes who were not pregnant, physical
activity, combined with diet and hypoglycaemic medication has
been shown to be effective in maintaining glycaemic control (
Tuomilehto 2001).
This evidence may not be generalisable to pregnant women with
pre-existing diabetes, but it does suggest that mild exercise during
pregnancy may have the potential to reduce the risk of complica-
tions associated with pre-existing diabetes.
The American College of Obstetricians and Gynecologists notes
that physical activity during pregnancy appears to have benefits
for most women and has few risks associated with it, although
some adaptation may be required, due to anatomical and physi-
ological changes in pregnancy (ACOG 2015). They recommend
that pregnant women have a clinical evaluation prior to starting
an exercise programme, to ensure that there are no medical con-
traindications, and that women be encouraged to participate in
aerobic and strength-conditioning exercises before, during, and
after uncomplicated pregnancies.
ACOG 2015 recommends that aerobic exercise during pregnancy
is contraindicated in a number of medical conditions, including:
1. cardiac disease;
2. restrictive lung disease;
3. incompetent cervix or cerclage;
4. multiple gestation at risk of preterm birth;
5. persistent second or third trimester bleeding;
6. placenta praevia after 26 weeks’ gestation;
7. preterm labour (current pregnancy);
8. ruptured membranes;
9. pre-eclampsia or pregnancy-induced hypertension;
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10. severe anaemia.
ACOG 2015 considers these activities are safe to continue with,
or initiate during an uncomplicated pregnancy, following medical
advice:
1. walking;
2. swimming;
3. stationary cycling;
4. low-impact aerobics;
5. modified yoga (avoiding positions that result in decreased
venous return);
6. modified Pilates;
7. racquet sports;
8. running or jogging;
9. strength training.
However, running, jogging, or strength training should only be
undertaken after consultation with an obstetrical care provider
(ACOG 2015). During pregnancy, the duration, frequency, and
intensity of physical activity may have to bemodified (Nascimento
2012).
ACOG 2015 recommends avoiding these activities during preg-
nancy:
1. contact sports (e.g. ice hockey, soccer, boxing);
2. activities with a high risk of falling (e.g. skiing, surfing, off-
road cycling);
3. scuba diving;
4. sky diving;
5. ’hot yoga’ or ’hot Pilates’.
How the intervention might work
Physical activity may improve glycaemic control in those with
types 1 and 2 diabetes because of the interaction between insulin
sensitivity and the uptake of glucose by skeletal muscles (Asano
2014). Skeletal muscle takes glucose from the blood using a mem-
brane transporter; improved insulin sensitivity following regular
physical activity can increase the efficiency of this transport mech-
anism (Chibalin 2000; Dela 1993; Hjeltnes 1998).
Why it is important to do this review
Pre-existing diabetes during pregnancy is associated with short-
and long-term adverse effects for the woman and her infant. Iden-
tifying interventions to improving health outcomes for women
with diabetes and their infants is a priority, as rates of diabetes
continue to increase. Exercise has been shown to have benefits for
non-pregnant individuals with pre-existing type 2 diabetes, such as
improving glycaemic control, and reducing visceral adipose tissue
and plasma triglycerides (Thomas 2006). The benefits and safety
for a woman during pregnancy and for her baby remains unclear.
O B J E C T I V E S
To evaluate the effects of exercise interventions for improving ma-
ternal and fetal outcomes in women with pre-existing diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include published or unpublished randomised controlled
trials or cluster-randomised trials in full text or abstract format.
Quasi-randomised and cross-over trials will be excluded. Confer-
ence abstracts will be handled in the same way as full-text publi-
cations.
Types of participants
Pregnant women diagnosed with pre-gestational diabetes (type 1
or type 2 diabetes), as defined by the trialists.
Women with gestational diabetes mellitus (GDM) will be ex-
cluded, as this will be covered in a separate Cochrane review
(Ceysens 2016).
Types of interventions
Wewill include any type of exercise programme, added to standard
care, targeted at women with known pre-gestational diabetes (type
1 or type 2 diabetes), at any stage of pregnancy compared with 1)
standard care alone or 2) standard care plus another intervention.
Types of outcome measures
Primary outcomes
Mother
1. Hypertensive disorders of pregnancy (as reported by the
trialists, and including pre-eclampsia, pregnancy-induced
hypertension, eclampsia);
2. Caesarean section.
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Neonate and infant
1. Large-for-gestational age (more than 4 kg);
2. Perinatal mortality (stillbirth and neonatal mortality);
3. Mortality or morbidity composite (variously defined by
trials, e.g. perinatal or infant death, shoulder dystocia, bone
fracture or nerve palsy);
4. Neurosensory disability (defined as any of the following:
legal blindness, sensorineural deafness requiring hearing aids,
moderate or severe cerebral palsy, developmental delay or
impairment (defined as developmental quotient less than two
standard deviations (SDs) below the mean).
Secondary outcomes
Short-term maternal outcomes
1. Induction of labour;
2. Perineal trauma;
3. Placental abruption;
4. Postpartum haemorrhage (more than 500 mL blood loss, or
otherwise defined by trialists);
5. Postpartum infection (as defined by trialists);
6. Weight gain during pregnancy;
7. Adherence to the intervention;
8. Behaviour changes associated with the intervention;
9. Relevant biomarker changes associated with the
intervention (e.g. adiponectin, free fatty acids, triglycerides, high
density lipoproteins, low density lipoproteins, insulin);
10. Sense of well-being and quality of life (as defined by
trialists);
11. Views of the intervention;
12. Breastfeeding (e.g. at discharge, six weeks postpartum);
13. Use of additional pharmacotherapy;
14. Glycaemic control during and at the end of treatment (as
defined by trialists);
15. Maternal hypoglycaemia;
16. Maternal mortality.
Long-term maternal outcomes
1. Postnatal depression (as defined by trialists);
2. Postnatal weight retention or return to pre-pregnancy
weight;
3. Body mass index (BMI);
4. Cardiovascular health (as defined by trialists, including
blood pressure (BP), hypertension, cardiovascular disease,
metabolic syndrome).
Neonatal and infant outcomes
1. Stillbirth;
2. Neonatal mortality;
3. Gestational age at birth;
4. Preterm birth (less than 37 weeks’ gestation, and less than
32 weeks’ gestation);
5. Apgar score (less than seven at five minutes);
6. Macrosomia (higher than 90th percentile);
7. Small-for-gestational age (lower than 10th percentile);
8. Birthweight and z-score;
9. Head circumference and z-score;
10. Length and z-score;
11. Ponderal index;
12. Adiposity (including skin fold thickness, neonatal fat mass);
13. Shoulder dystocia;
14. Bone fracture;
15. Nerve palsy;
16. Respiratory distress syndrome;
17. Hypoglycaemia requiring treatment (as defined by trialists);
18. Hyperbilirubinaemia (as defined by trialists);
19. Neonatal hypocalcaemia (as defined by trialists);
20. Polycythaemia (as defined by trialists);
21. Relevant biomarker changes associated with the
intervention (e.g. cord C-peptide, cord insulin).
Later infant and childhood outcomes
1. Weight and z-scores;
2. Height and z-scores;
3. Head circumference and z-scores;
4. Adiposity (e.g. as measured by BMI, skinfold thickness);
5. BP;
6. Type 1 diabetes;
7. Type 2 diabetes;
8. Impaired glucose tolerance;
9. Dyslipidaemia or metabolic syndrome;
10. Educational achievement.
Child and adult outcomes
1. Weight;
2. Height;
3. Adiposity (e.g. as measured by BMI, skinfold thickness);
4. Cardiovascular health (as defined by trialists, including BP,
hypertension, cardiovascular disease, metabolic syndrome);
5. Type 1 diabetes;
6. Type 2 diabetes;
7. Impaired glucose tolerance (as defined by trialists);
8. Dyslipidaemia or metabolic syndrome (as defined by
trialists);
9. Employment, education, social status and achievement.
Health service use
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1. Number of hospital or health professional visits (e.g.
midwife, obstetrician, physician, dietitian, diabetic nurse);
2. Number of antenatal visits or admissions;
3. Length of antenatal stay;
4. Neonatal intensive care unit admission;
5. Length of postnatal stay (mother);
6. Length of postnatal stay (baby);
7. Costs to families associated with the management provided;
8. Costs associated with the intervention;
9. Cost of maternal care;
10. Cost of offspring care.
Search methods for identification of studies
The following methods sections of this protocol are based on a
standard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We will search Cochrane Pregnancy and Childbirth’s Trials Regis-
ter by contacting their Information Specialist.
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter, including the detailed search strategies for CENTRAL,MED-
LINE, Embase, and CINAHL, the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about Cochrane Pregnancy and Childbirth in
the Cochrane Library, and select the ‘Specialized Register’ section
from the options on the left side of the screen.
Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals,
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in amore specific search set that will be fully
accounted for in the relevant review sections (Included, Excluded,
Awaiting Classification, or Ongoing).
In addition, we will search ClinicalTrials.gov and the WHO In-
ternational Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned, and ongoing trial reports. The search terms we
will use are given in Appendix 1.
Searching other resources
We will search the reference lists of retrieved studies. We will not
apply any language or date restrictions.
Data collection and analysis
Selection of studies
Two review authors will independently assess for inclusion, all the
potential studies we identify as a result of the search strategy. We
will resolve any disagreement through discussion, or if required,
we will consult a third person.
We will create a study flow diagram to map out the number of
records identified, included, and excluded.
Data extraction and management
We will design a form to extract data. For eligible studies, two re-
view authors will independently extract the data using the agreed
form. We will resolve discrepancies through discussion, or if re-
quired, we will consult a third person. We will enter data into Re-
view Manager 5 software and check for accuracy (RevMan 2014).
When information regarding any of the above is unclear, we will
attempt to contact authors of the original reports to provide fur-
ther details.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study, using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve
any disagreement by discussion, or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
For each included study, we will describe the method used to
generate the allocation sequence in sufficient detail to allow an
assessment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
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• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For each included study, we will describe the method used to
conceal allocation to interventions prior to assignment, and will
assess whether intervention allocation could have been foreseen in
advance of, during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study, we will describe the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes.
We will assess the methods as:
• low, high, or unclear risk of bias for participants;
• low, high, or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study, we will describe the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high, or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data)
For each included study, and for each outcome or class of out-
comes, we will describe the completeness of data including attri-
tion and exclusions from the analysis. We will state whether attri-
tion and exclusions were reported, and the numbers included in
the analysis at each stage (comparedwith the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses that we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For each included study, we will describe how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
For each included study, we will describe any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
Handbook of Systematic Reviews of Interventions (Higgins 2011).
With reference to (1) to (6) above, we will assess the likely magni-
tude and direction of the bias and whether we consider it is likely
to impact on the findings. We will explore the impact of the level
of bias through undertaking sensitivity analyses - see Sensitivity
analysis.
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Assessment of the quality of the evidence using the
GRADE approach
The quality of the evidence will be assessed for outcomes relating
to the mother and for the infant, child, or adult for the main com-
parisons, using the GRADE approach, outlined in the GRADE
handbook and Chapters 11 and 12 of the Cochrane Handbook of
Systematic Reviews of Interventions (Higgins 2011).
Maternal
1. Hypertensive disorders of pregnancy (as reported by
trialists, including pre-eclampsia, pregnancy-induced
hypertension, eclampsia)
2. Caesarean section
3. Perineal trauma
4. Postnatal weight retention or return to pre-pregnancy
weight
5. Postnatal depression (as defined by trialists)
6. Induction of labour
Child (as a fetus, neonate, child, adult)
1. Large-for-gestational age (more than 4 kg)
2. Perinatal mortality (stillbirth and neonatal mortality)
3. Mortality and morbidity composite (variously defined by
trials, e.g. perinatal or infant death, shoulder dystocia, bone
fracture or nerve palsy)
4. Hypoglycaemia requiring treatment (as defined by trialists)
5. Adiposity (including skin fold thickness, neonatal fat mass)*
6. Diabetes (type 1, type 2)*
7. Neurosensory disability (defined as any of the following:
legal blindness, sensorineural deafness requiring hearing aids,
moderate or severe cerebral palsy, developmental delay or
impairment (defined as developmental quotient less than two
standard deviations (SDs) below the mean)
GRADEpro Guideline Development Tool will be used to import
data from Review Manager 5.3 (RevMan 2014) in order to create
’Summary of findings’ tables. A summary of the intervention effect
and a measure of quality for each of the above outcomes will be
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
*These outcomes will be reported for each stage of life where data
are reported.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as a summary risk
ratio (RR) with 95% confidence intervals (CI).
Continuous data
For continuous data, we will use the mean difference (MD) with
95% CI if outcomes are measured in the same way between trials.
We will use the standardised mean difference (SMD)with 95%CI
to combine trials that measure the same outcome, but use different
methods.
Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually-randomised trials. If any included studies are cluster-
randomised trials, we will make adjustments using the methods
described in the Cochrane Handbook of Systematic Reviews for In-
terventions (Section 16.3.4 or 16.3.6), using an estimate of the in-
tra-cluster correlation co-efficient (ICC) derived from the trial (if
possible), from a similar trial, or from a study of a similar popula-
tion (Higgins 2011). If we use ICCs from other sources, we will
report this and conduct sensitivity analyses to investigate the effect
of variation in the ICC.We will consider it reasonable to combine
the results from both cluster-randomised trials and individually-
randomised trials if there is little heterogeneity between the study
designs, and is unlikely there will be an interaction between the ef-
fect of intervention and the choice of randomisation unit. If clus-
ter-randomised trials are included, we will seek statistical advice
on the appropriate analysis to enable us to include the data in the
meta-analyses.
Other unit of analysis issues
Multiple pregnancy
There may be unit of analysis issues that arise when the women
randomised have a multiple pregnancy. We will present maternal
data as per woman randomised, and neonatal data per infant.
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Multiple-arm studies
Where a trial has multiple intervention arms, we will avoid ’double
counting’ participants by combining groups to create a single pair-
wise comparison, if possible. Where this is not possible, we will
split the ’shared’ group into two or more groups with smaller
sample sizes, and include two or more (reasonably independent)
comparisons.
Dealing with missing data
For included studies, we will note levels of attrition. We will ex-
plore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by performing a
sensitivity analysis.
For all outcomes, we will carry out analyses, as far as possible,
on an intention-to-treat basis, i.e. we will attempt to include all
participants randomised to each group in the analyses, and all
participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial
will be the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the Tau², I², and Chi² statistics. We will regard heterogeneity as
substantial, if I² is greater than 30%, and either Tau² is greater
than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
We will carry out statistical analysis using the Review Manager 5
software (RevMan 2014). We will use fixed-effect meta-analysis
for combining datawhere it is reasonable to assume that studies are
estimating the same underlying treatment effect: i.e. where trials
are examining the same intervention, and the trials’ populations
and methods are judged sufficiently similar. If there is clinical het-
erogeneity sufficient to expect that the underlying treatment ef-
fects differ between trials, or if substantial statistical heterogeneity
is detected, we will use random-effects meta-analysis to produce
an overall summary, if an average treatment effect across trials is
considered clinically meaningful. The random-effects summary
will be treated as the average of the range of possible treatment
effects, and we will discuss the clinical implications of treatment
effects differing between trials. If the average treatment effect is
not clinically meaningful, we will not combine trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it using
subgroup and sensitivity analyses. We will consider whether an
overall summary is meaningful, and if it is, use random-effects
analysis to produce it.
We plan to carry out the following subgroup analyses.
1. Group exercise versus individual exercise;
2. Low-intensity exercise (cumulative duration of exercise at
50% VO2 max (maximal oxygen consumption) for shorter than
180 minutes) versus high-intensity exercise (cumulative duration
of exercise at 50% VO2 max) for longer than 180 minutes.
We will test the following primary outcomes in subgroup analysis.
Maternal outcomes
1. Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia);
2. Caesarean section
Neonatal outcomes
1. Large-for-gestational age;
2. Perinatal mortality (stillbirth and neonatal mortality);
3. Mortality or morbidity composite (variously defined by
trials, e.g. perinatal or infant death, shoulder dystocia, bone
fracture, or nerve palsy);
4. Neurosensory disability.
We will assess subgroup differences with the interaction tests avail-
able within RevMan 5 (RevMan 2014). We will report the results
of subgroup analyses quoting the Chi² statistic and P value, and
the I² value.
Sensitivity analysis
If there is evidence of substantial heterogeneity, we will explore
this by assessing the impact of the risks of bias of the included
trials for the primary outcomes.
Maternal outcomes
1. Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia);
2. Caesarean section
Neonatal outcomes
1. Large-for-gestational age;
2. Perinatal mortality (stillbirth and neonatal mortality);
3. Mortality or morbidity composite (variously defined by
trials, e.g. perinatal or infant death, shoulder dystocia, bone
fracture, or nerve palsy);
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4. Neurosensory disability.
We will compare trials that have low risk of bias for allocation
concealment with those judged to be of unclear or high risk of
bias; conference abstracts will be excluded from the meta-analysis.
We will also investigate the effect of the randomisation unit (i.e.
where we include cluster-randomised trials along with individu-
ally-randomised trials).
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